251 related articles for article (PubMed ID: 33064705)
21. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
Koshkin VS; Grivas P
Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Huang J; Reckamp KL
Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
[TBL] [Abstract][Full Text] [Related]
23. First-Line Treatment of Non-Small-Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors.
Bylicki O; Barazzutti H; Paleiron N; Margery J; Assié JB; Chouaïd C
BioDrugs; 2019 Apr; 33(2):159-171. PubMed ID: 30825132
[TBL] [Abstract][Full Text] [Related]
24. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Chism DD
J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
[TBL] [Abstract][Full Text] [Related]
25. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
Nishijima TF; Shachar SS; Nyrop KA; Muss HB
Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
[TBL] [Abstract][Full Text] [Related]
26. PD-1/PD-L1-dependent immune response in colorectal cancer.
Payandeh Z; Khalili S; Somi MH; Mard-Soltani M; Baghbanzadeh A; Hajiasgharzadeh K; Samadi N; Baradaran B
J Cell Physiol; 2020 Jul; 235(7-8):5461-5475. PubMed ID: 31960962
[TBL] [Abstract][Full Text] [Related]
27. Immune checkpoint inhibitors for nonsmall cell lung cancer treatment.
Chen YM
J Chin Med Assoc; 2017 Jan; 80(1):7-14. PubMed ID: 27693088
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM
Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866
[TBL] [Abstract][Full Text] [Related]
29. Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis.
Sun X; Roudi R; Dai T; Chen S; Fan B; Li H; Zhou Y; Zhou M; Zhu B; Yin C; Li B; Li X
BMC Cancer; 2019 Jun; 19(1):558. PubMed ID: 31182061
[TBL] [Abstract][Full Text] [Related]
30. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
31. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of PD-1/PD-L1 inhibitors in the treatment of lung cancer: Brightness and challenge.
Yang Y; Yu Y; Lu S
Sci China Life Sci; 2020 Oct; 63(10):1499-1514. PubMed ID: 32303964
[TBL] [Abstract][Full Text] [Related]
33. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.
Verhoeven Y; Quatannens D; Trinh XB; Wouters A; Smits ELJ; Lardon F; De Waele J; van Dam PA
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670397
[TBL] [Abstract][Full Text] [Related]
34. Novel Therapeutics for Recurrent Cervical Cancer: Moving Towards Personalized Therapy.
Cohen AC; Roane BM; Leath CA
Drugs; 2020 Feb; 80(3):217-227. PubMed ID: 31939072
[TBL] [Abstract][Full Text] [Related]
35. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
[TBL] [Abstract][Full Text] [Related]
38. PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay.
Cimadamore A; Massari F; Santoni M; Lopez-Beltran A; Cheng L; Scarpelli M; Montironi R; Moch H
Curr Drug Targets; 2020; 21(16):1664-1671. PubMed ID: 32208115
[TBL] [Abstract][Full Text] [Related]
39. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
40. Advances in immunotherapy for cervical cancer.
Wendel Naumann R; Leath CA
Curr Opin Oncol; 2020 Sep; 32(5):481-487. PubMed ID: 32740092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]